scholarly journals NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases

Biomolecules ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 904 ◽  
Author(s):  
Ángel Cores ◽  
Marta Piquero ◽  
Mercedes Villacampa ◽  
Rafael León ◽  
J. Carlos Menéndez
Keyword(s):  
Gene Expression ◽  
Neurodegenerative Diseases ◽  
Protein Degradation ◽  
Phase Ii ◽  
Drug Targets ◽  
Antioxidant Response ◽  
Potential Drug ◽  
Critical Overview ◽  
Potential Drug Targets ◽  
Potential Use

NRF2 acts by controlling gene expression, being the master regulator of the Phase II antioxidant response, and also being key to the control of neuroinflammation. NRF2 activity is regulated at several levels, including protein degradation by the proteasome, transcription, and post-transcription. The purpose of this review is to offer a concise and critical overview of the main mechanisms of NRF2 regulation and their actual or potential use as targets for the treatment of neurodegenerative diseases.

scholarly journals RNA interference: what it is and what it does: A potent gene regulator

2004 ◽  
Vol 26 (5) ◽  
pp. 7-10
Author(s):  
Darcey Black ◽  
Sarah Newbury
Keyword(s):  
Gene Expression ◽  
Gene Regulation ◽  
Rna Interference ◽  
Metabolic Pathways ◽  
Drug Targets ◽  
Human Cells ◽  
Potential Drug ◽  
Genetic Studies ◽  
Multicellular Organisms ◽  
Potential Drug Targets

RNA interference (RNAi) is a potent and specific way of down-regulating gene expression. It is effective in most multicellular organisms, and every gene in the genome can potentially be targeted, providing that the sequence of the gene is known. It has provided a breakthrough in the study of gene regulation, because the function of a gene can often be deduced by inhibiting its ex-pression. RNAi therefore provides a rapid way of studying the function of known genes in organisms where genetic studies are difficult. Since RNAi is effective in human cells, it is now being used in several ways. These include the elucidation of biochemical and metabolic pathways, validation of potential drug targets, and as a therapeutic in the treatment of disease.

scholarly journals LncRNAs and the Angiogenic Switch in Cancer: Clinical Significance and Therapeutic Opportunities

Genes ◽  
2022 ◽  
Vol 13 (1) ◽  
pp. 152
Author(s):  
Peace Mabeta ◽  
Rodney Hull ◽  
Zodwa Dlamini
Keyword(s):  
Blood Vessels ◽  
Drug Targets ◽  
Patient Survival ◽  
Angiogenic Factors ◽  
Potential Drug ◽  
Hallmarks Of Cancer ◽  
Ribonucleic Acids ◽  
Angiogenic Switch ◽  
Potential Drug Targets ◽  
Potential Use

Angiogenesis is one of the hallmarks of cancer, and the establishment of new blood vessels is vital to allow for a tumour to grow beyond 1–2 mm in size. The angiogenic switch is the term given to the point where the number or activity of the pro-angiogenic factors exceeds that of the anti-angiogenic factors, resulting in the angiogenic process proceeding, giving rise to new blood vessels accompanied by increased tumour growth, metastasis, and potential drug resistance. Long noncoding ribonucleic acids (lncRNAs) have been found to play a role in the angiogenic switch by regulating gene expression, transcription, translation, and post translation modification. In this regard they play both anti-angiogenic and pro-angiogenic roles. The expression levels of the pro-angiogenic lncRNAs have been found to correlate with patient survival. These lncRNAs are also potential drug targets for the development of therapies that will inhibit or modify tumour angiogenesis. Here we review the roles of lncRNAs in regulating the angiogenic switch. We cover specific examples of both pro and anti-angiogenic lncRNAs and discuss their potential use as both prognostic biomarkers and targets for the development of future therapies.

Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle

2014 ◽  
Vol 15 (3) ◽  
pp. 255-271 ◽  
Author(s):  
Rubem Sadok Menna-Barreto ◽  
Kele Belloze ◽  
Jonas Perales ◽  
Floriano Silva-Jr
Keyword(s):  
Trypanosoma Cruzi ◽  
Drug Targets ◽  
Bioinformatic Analysis ◽  
Potential Drug ◽  
Potential Drug Targets

Structure, Function and Interactions of Tau: Particular Focus on Potential Drug Targets for the Treatment of Tauopathies

2018 ◽  
Vol 17 (5) ◽  
pp. 325-337 ◽  
Author(s):  
Hojjat Borna ◽  
Kasim Assadoulahei ◽  
Gholamhossein Riazi ◽  
Asghar Beigi Harchegani ◽  
Alireza Shahriary
Keyword(s):  
Tau Protein ◽  
Drug Targets ◽  
Brain Injuries ◽  
Potential Drug ◽  
Microtubule Network ◽  
Wide Range ◽  
Potential Risk Factors ◽  
Range Of Functions ◽  
Potential Drug Targets

Background & Objective: Neurodegenrative diseases are among the most widespread lifethreatening disorders around the world in elderly ages. The common feature of a group of neurodegenerative disorders, called tauopathies, is an accumulation of microtubule associated protein tau inside the neurons. The exact mechanism underlying tauopathies is not well-understood but several factors such as traumatic brain injuries and genetics are considered as potential risk factors. Although tau protein is well-known for its key role in stabilizing and organization of axonal microtubule network, it bears a broad range of functions including DNA protection and participation in signaling pathways. Moreover, the flexible unfolded structure of tau facilitates modification of tau by a wide range of intracellular enzymes which in turn broadens tau function and interaction spectrum. The distinctive properties of tau protein concomitant with the crucial role of tau interaction partners in the progression of neurodegeneration suggest tau and its binding partners as potential drug targets for the treatment of neurodegenerative diseases. Conclusion: This review aims to give a detailed description of structure, functions and interactions of tau protein in order to provide insight into potential therapeutic targets for treatment of tauopathies.

Sign in / Sign up

Export Citation Format

Share Document